- Home
- RHLD vs EDIT Comparison
RHLD vs EDIT Comparison
Compare RHLD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHLD
- EDIT
- Stock Information
- Founded
- RHLD 2024
- EDIT 2013
- Country
- RHLD United States
- EDIT United States
- Employees
- RHLD N/A
- EDIT N/A
- Industry
- RHLD
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RHLD
- EDIT Health Care
- Exchange
- RHLD NYSE
- EDIT Nasdaq
- Market Cap
- RHLD 217.1M
- EDIT 179.1M
- IPO Year
- RHLD N/A
- EDIT 2016
- Fundamental
- Price
- RHLD $37.22
- EDIT $2.88
- Analyst Decision
- RHLD
- EDIT Buy
- Analyst Count
- RHLD 0
- EDIT 12
- Target Price
- RHLD N/A
- EDIT $6.20
- AVG Volume (30 Days)
- RHLD 100.9K
- EDIT 3.5M
- Earning Date
- RHLD 08-15-2025
- EDIT 08-06-2025
- Dividend Yield
- RHLD N/A
- EDIT N/A
- EPS Growth
- RHLD N/A
- EDIT N/A
- EPS
- RHLD 12.54
- EDIT N/A
- Revenue
- RHLD $420,450,000.00
- EDIT $35,837,000.00
- Revenue This Year
- RHLD N/A
- EDIT N/A
- Revenue Next Year
- RHLD N/A
- EDIT N/A
- P/E Ratio
- RHLD $3.18
- EDIT N/A
- Revenue Growth
- RHLD 11.09
- EDIT N/A
- 52 Week Low
- RHLD $24.22
- EDIT $0.91
- 52 Week High
- RHLD $54.05
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- RHLD N/A
- EDIT 74.64
- Support Level
- RHLD N/A
- EDIT $2.48
- Resistance Level
- RHLD N/A
- EDIT $3.24
- Average True Range (ATR)
- RHLD 0.00
- EDIT 0.25
- MACD
- RHLD 0.00
- EDIT 0.07
- Stochastic Oscillator
- RHLD 0.00
- EDIT 84.84
About RHLD RESOLUTE HOLDINGS MANAGEMENT INC
Resolute Holdings Management Inc is provide operating management services. The company has two operating segments and two reportable segments: Payment Card and Arculus. Payment Card generates its revenue through the production and sale of metal payment cards while Arculus generates its revenue through the production and sale of metal payment or nonpayment cards containing Arculus technology for authentication and/or digital asset cold storage and related services. The company generates maximum revenue Domestically.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.